Esteban Braggio

Toyota Motor Corporation (Switzerland) — Switzerland

Medicine · Health Sciences

48h-index10.2kcitations506works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(230), Multiple Myeloma Research and Treatments(169), Protein Degradation and Inhibitors(107), Lymphoma Diagnosis and Treatment(86), Immunodeficiency and Autoimmune Disorders(50)

Publications506 total

Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemia
Haematologica·2025Open Access
Supplementary Figure 4 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 3 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Data 1 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 2 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 1 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 7 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 5 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 6 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 8 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 9 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Genomic profiling reveals molecular heterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL)
Leukemia Research·2025Open Access
CHIP amplifies the risk of lymphoid malignancies in individuals with monoclonal B-cell lymphocytosis (MBL)
Blood Cancer Journal·2025Open Access
The predictive value of mosaic chromosomal alterations for lymphoid malignancies varies by monoclonal B-cell lymphocytosis status
Blood·2025
IL-4 epigenetically reprograms CART19-28ζ cells to drive dysfunction
Blood·2025Open Access
Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma
Blood·2025Open Access
Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population
Blood·2025
Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)
Blood·2025
Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma
Blood·2025Open Access
Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators
Blood·2025Open Access
page 1 of 26Next →

Frequent Co-authors

Rafaël Fonseca(32), A. Keith Stewart(21), P. Leif Bergsagel(15), Chang-Xin Shi(11), Laura A. Bruins(11), Neil E. Kay(9), K. Martin Kortüm(9), Jonathan J. Keats(8), Tait D. Shanafelt(8), Yuan Xiao Zhu(8), Ahmet Doǧan(8), John D. Carpten(7), Jan B. Egan(7), Jessica Schmidt(7), Scott Van Wier(6), Shaji Kumar(6), S. Vincent Rajkumar(6), Thomas E. Witzig(6), Stephen M. Ansell(6), Patrick Jedlowski(6)